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Type 2 diabetes (T2D) shares some common risk factors with psoriasis. We evaluated the association between
psoriasis and the risk of incident T2D among women and men in the United States in a mixed
retrospective–prospective cohort study. A total of 184,395 participants were included from an older cohort of
women (the Nurses’ Health Study (NHS); 1996–2008), a younger cohort of women (NHS II; 1991–2007), and an
older cohort of men (Health Professionals’ Follow-Up Study (HPFS); 1986–2006). During 2,700,958 person-years of
follow-up, 9,938 incident T2D cases were confirmed. We found a significantly increased risk of T2D associated
with psoriasis only among younger women (NHS II; multivariate-adjusted relative risk (RR)¼ 1.25, 95%
confidence interval (CI): 1.05–1.49). When only including those younger than 60 years during follow-up (NHS
and HPFS), we observed a nonsignificant trend toward increased risk for T2D. In a pooled analysis of the three
cohorts, psoriatics younger than 60 years were at a higher risk of T2D (RR 1.26, 95% CI: 1.08–1.48 for women and
RR 1.26, 95% CI: 1.08–1.46 for both sexes combined). In addition, the risk of T2D was much higher for those
developing psoriasis at an early age. In conclusion, we found an association between psoriasis and the risk of
T2D among individuals younger than 60 years.
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INTRODUCTION
Psoriasis is a common immune-mediated disease of the skin
characterized by inflammatory and hyperproliferative
changes (Lowes et al., 2007). Now considered a systemic
disorder, psoriasis affects populations all over the world, with
an estimated prevalence of 2.2–2.6% in the United States
(Gelfand et al., 2005). Although the etiology remains to
be elucidated further, present evidence suggests that psoriasis
pathophysiology involves the interaction of genetic predis-
position, immune response, and environmental risk
factors such as smoking, alcohol intake, and obesity
(Gudjonsson et al., 2004; Setty et al., 2007a, b; Loffredo
et al., 2009; Qureshi et al., 2010).
Diabetes has been a major public health concern in the
United States, with a prevalence of 8.3% in 2010 (http://
www.cdc.gov/diabetes/pubs/estimates11.htm#1, accessed 22
June 2011). The prevalence of comorbidities such as insulin
resistance, metabolic syndrome, and type 2 diabetes (T2D)
associated with psoriasis has gained interest in recent years,
and most studies on this topic have been cross-sectional
(Lindegard, 1986; Henseler and Christophers, 1995; Pearce
et al., 2005; Neimann et al., 2006; Cohen et al., 2008;
Kimball et al., 2008; Driessen et al., 2009; Love et al.,
2011) or case–control studies (Sommer et al., 2006; Gisondi
et al., 2007; Shapiro et al., 2007; Brauchli et al., 2008;
Gerdes et al., 2008; Naldi et al., 2008; Wu et al., 2008;
Vena et al., 2010), and inflammation seems to be an
underlying mechanism (Pradhan et al., 2001; Hu et al.,
2004; Davidovici et al., 2010).
There have been three cohort studies on this topic, and
two of them did not adjust for the major risk factors of T2D
(Kaye et al., 2008; Solomon et al., 2010). Another cohort
study was a preliminary report from our group (Qureshi et al.,
2009). In that analysis, diabetes and hypertension were
evaluated as independent outcomes and it only utilized
participants from NHS II. We had not obtained the complete
data for women with psoriasis and no confirmed cases of
psoriasis and T2D were used at that time. Although that study
obtained a significant association, covariates were not fully
adjusted for. Therefore, further evidence from large cohort
studies is warranted to evaluate the association. In our study
& 2012 The Society for Investigative Dermatology www.jidonline.org 291
ORIGINAL ARTICLE
Received 24 May 2011; revised 26 June 2011; accepted 24 July 2011;
published online 13 October 2011
1Department of Dermatology, Brigham and Women’s Hospital and Harvard
Medical School, Boston, Massachusetts, USA; 2Channing Laboratory,
Department of Medicine, Brigham and Women’s Hospital and Harvard
Medical School, Boston, Massachusetts, USA; 3Department of Epidemiology,
Harvard School of Public Health, Boston, Massachusetts, USA and
4Department of Nutrition, Harvard School of Public Health, Boston,
Massachusetts, USA
Correspondence: Abrar A. Qureshi, Department of Dermatology, Brigham
and Women’s Hospital, Harvard Medical School, 45 Francis Street, 221L,
Boston, Massachusetts 02115, USA.
E-mail: aqureshi@bics.bwh.harvard.edu or aqureshi@partners.org
Abbreviations: BMI, body mass index; CI, confidence interval; HPFS, Health
Professionals’ Follow-Up Study; NHS, Nurses’ Health Study; RR, relative risk;
T2D, type 2 diabetes
we investigated the association between psoriasis and T2D
in a total population of 184,395 participants from the Nurses’
Health Study (NHS), NHS II, and Health Professionals’
Follow-Up Study (HPFS). It has been recognized that psoriasis
occurs in a bimodal age distribution and type 1 psoriasis
is generally early onset, severe, and hereditary (females, 16
years; males, 22 years), whereas type 2 psoriasis is late onset
(females, 60 years; males, 57 years; Henseler and Christo-
phers, 1985; Langley et al., 2005). Therefore, we performed
analysis for those younger than 60 years during the follow-
up and evaluated age as a potential effect modifier of
the association between psoriasis and the risk of incident
T2D. In addition to analyses in individual cohorts, combined
analyses from different cohorts were performed to explore the
association further.
RESULTS
A total of 184,395 participants were included, including
63,927 women from NHS, 95,779 women from NHS II, and
24,689 men from HPFS. Characteristics of the participants
according to the diagnosis of psoriasis at the beginning of the
follow-up are listed in Table 1. The mean age was sharply
different among three cohorts. In addition, women and men
with psoriasis were more likely to be smokers and have
higher body mass index (BMI).
After 735,664, 1,496,867, and 468,427 person-years of
follow-up, we documented 4,280, 3,968, and 1,690 incident
T2D from NHS, NHS II, and HPFS, respectively. For NHS II,
psoriasis was associated with an elevated risk of T2D, and
age-adjusted and multivariate-adjusted relative risks (RRs)
were 1.76 (95% confidence interval (CI): 1.48–2.09) and 1.25
(95% CI: 1.05–1.49), respectively. BMI is a known major risk
factor mediating the risk of diabetes and psoriasis indepen-
dently. We found differences in the association between
psoriasis and diabetes when adjusting for only age and
BMI (RR¼1.33, 95% CI: 1.12–1.58) versus not adjusting for
BMI but other covariates (RR¼1.50, 95% CI: 1.26–1.78). For
NHS and HPFS, no significant association was found
in multivariable analysis (Table 2).
We performed further analyses by including only those
younger than 60 years during the follow-up (Table 3). For
NHS and HPFS, 28,834 and 20,708 participants were
included, respectively. All the NHS II participants were
younger than 60 years before the return date of 2005
questionnaire. Although analyses did not reach statistical
significance in multivariate models, increased RRs were
observed among those younger than 60 years in the NHS
(RR¼ 1.35, 95% CI: 0.89–2.05) and HPFS (RR¼ 1.20, 95%
CI: 0.79–1.82), which are very similar to what we observed in
NHS II. Pooled results of NHS and NHS II indicated that
psoriasis was associated with a 26% increased risk of
T2D (RR¼1.26, 95% CI: 1.06–1.48) in women younger than
60 years. For all participants younger than 60 years during the
follow-up, pooled results of the three cohorts indicated that
psoriasis was associated with a 26% increased risk of T2D
(RR¼ 1.26, 95% CI: 1.08–1.46). No heterogeneity was
observed among these cohorts (P¼ 0.919 and 0.731 for
NHS/NHS II/HPFS, and NHS/NHS2, respectively).
Table 1. Baseline characteristics of study participants in three US cohort studies1
NHS (N=63,927) NHS II (N=95,779)
HPFS
(N=24,689)
No psoriasis,
N=62,738
Psoriasis,
N=1,189
No psoriasis,
N=94,437
Psoriasis,
N=1,342
No psoriasis,
N=24,146
Psoriasis,
N=543
Age, mean (SD), years 60.9 (6.8) 61.2 (6.8) 36.2 (4.6) 36.7 (4.6) 50.5 (8.0) 50.8 (8.1)
Race (white, %) 95.7 96.6 95.3 96.7 96.0 95.8
BMI, kgm–2, mean (SD) 26.2 (4.9) 27.1 (5.4) 24.5 (5.0) 25.4 (5.6) 24.8 (4.4) 25.2 (4.3)
Alcohol intake, g day–1, mean
(SD)
4.6 (8.6) 5.0 (9.9) 2.9 (5.7) 2.9 (5.4) 11.1 (14.5) 11.9 (16.1)
Physical activity, metabolic
equivalent hours per wk,
mean (SD)
18.6 (22.4) 16.4 (19.1) 18.8 (26.2) 17.8 (26.2) 22.2 (29.4) 24.4 (34.7)
Current smoking (%) 10.6 14.5 11.5 15.2 6.9 9.2
Family history of diabetes (%) 26.5 28.0 16.3 18.9 14.0 14.7
Postmenopausal hormone (%) 59.0 60.9 2.6 3.7 NA NA
Hypertension (%) 26.5 29.2 3.1 4.6 15.6 17.9
Hypercholesterolemia (%) 34.6 36.3 8.9 13.1 10.7 11.8
Aspirin use (%) 51.2 51.3 11.1 12.9 26.2 25.4
Multivitamin use (%) 49.2 46.7 38.7 40.2 40.8 41.4
Abbreviations: BMI, body mass index; HPFS, Health Professionals’ Follow-Up Study; NA, not applicable; NHS, Nurses’ Health Study.
1Characteristics of participants at the beginning of follow-up (return date of the 1996, 1991, and 1986 questionnaires, respectively, for NHS, NHS II, and
HPFS).
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We analyzed the association of age of psoriasis diagnosis
with the risk of incident T2D for NHS II. We obtained
significant results only for cases diagnosed at o40 years
(RR¼ 1.81, 95% CI: 1.14–2.89) rather than those diagnosed
at 40–49 or X50 years (Table 4).
We evaluated the effect modification of menopausal status
and postmenopausal hormone use in NHS II, but no marked
differences were found among premenopausal women,
and postmenopausal hormone never or past/current users
(available upon request). Given few premenopausal women
among NHS, we cannot perform pooled analysis of
premenopausal women in NHS/NHS II.
We performed analysis by using confirmed psoriatics in
NHS and NHS II. Analysis showed that individuals with
confirmed psoriasis in NHS II were associated with a
significantly increased risk of incident T2D, and multi-
variate-adjusted RR was 1.46 (95% CI: 1.16–1.83; Table 5).
In NHS, the RR among younger participants was 1.40 (95%
CI: 0.87–2.23).
A sensitivity analysis was performed by excluding
participants with baseline heart disease or cancer and the
results did not change markedly. In addition, we performed
an analysis by excluding the T2D incident cases that
occurred within the first time period of follow-up and noticed
no remarkable differences either (available upon request).
DISCUSSION
On the basis of the three large cohort studies, our study
examined the association between psoriasis and incident
T2D among all participants and those younger than 60 years
during the follow-up. We found that psoriasis was associated
with an elevated risk of incident T2D among younger
individuals with psoriasis.
Past basic research and epidemiological studies have
provided evidence that psoriasis and T2D share common risk
factors. Psoriasis has been recognized as a chronic inflam-
matory disease associated with expansion and activation
of Th1 and Th17 T cells in the skin, with upgraded production
of cytokines such as tumor necrosis factor, C-reactive protein,
IL-6, and so on (Lowes et al., 2008; Davidovici et al., 2010).
Past studies have also suggested an inflammatory basis
for diabetes, and low-grade inflammation has been shown
to precede and predict the development of insulin resistance
and diabetes (Duncan et al., 2003; Garcia et al., 2010).
Specifically, inflammatory cytokines such as IL-6 and
tumor necrosis factor have been associated with insulin
resistance and T2D (Pradhan et al., 2001; Hu et al., 2004). In
addition, leptin and adiponection may be involved
in psoriasis and T2D, suggesting the role of adipocytokines
in linking the two diseases (Takahashi et al., 2008).
Moreover, environmental factors like smoking may have an
impact on the risk of both psoriasis and T2D (Willi et al.,
2007; Setty et al., 2007b). Therefore, immune-mediated
inflammatory process, metabolic biomarkers, and environ-
mental factors could be the potential links between psoriasis
and diabetes.
There have been cross-sectional or case–control studies
investigating the association between psoriasis and T2D,
suggesting psoriasis as a risk predictor for diabetes, with the
odds ratio ranging from 1.1 to 2.8. In view of their cross-
sectional design or retrospective nature, these results may
have been affected by selection and information bias.
Moreover, these results can only reflect the relationship
between psoriasis and diabetes prevalence in certain
populations at best rather than diabetes incidence. In
addition, two cohort studies were carried out that did not
adjust for the main confounders (Kaye et al., 2008; Solomon
et al., 2010). Our results showed general agreement with past
epidemiological studies, and the association seems to be
modest and only among younger participants.
Table 2. Relative risks of incident type 2 diabetes according to psoriasis among US women and men
Study Diabetes cases Person-years Age-adjusted RR (95% CI) Multivariate RR (95% CI)1 Multivariate RR (95% CI)2
NHS 4,280 735,664
No psoriasis 4,171 720,650 1.00 1.00 1.00
Psoriasis 109 15,014 1.23 (1.02–1.49) 1.14 (0.95–1.38) 1.01 (0.83–1.22)
NHS II 3,968 1,496,867
No psoriasis 3,835 1,470,709 1.00 1.00 1.00
Psoriasis 133 26,159 1.76 (1.48–2.09) 1.50 (1.26–1.78) 1.25 (1.05–1.49)
HPFS 1,690 468,427
No psoriasis 1,638 455,263 1.00 1.00 1.00
Psoriasis 52 13,163 1.05 (0.80–1.38) 0.94 (0.71–1.25) 0.91 (0.69–1.20)
Abbreviations: CI, confidence interval; HPFS, Health Professionals’ Follow-Up Study; NHS, Nurses’ Health Study; RR, relative risk.
1Simultaneously adjusted for age, smoking (never, past, and current with 1–14, 15–24, or X25 cigarettes per day), alcohol intake (no, o4.9, 5.0–14.9, or
X15.0 g day–1), physical activity (o3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, or X27.0 metabolic equivalent hours per wk), race (Caucasian, Asian, Hispanic, or
African American), family history of diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no),
multivitamin use (yes or no), and postmenopausal hormone use (for women only, premenopause, never, current, or past users).
2Simultaneously adjusted for all the variables listed above and body mass index (o21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9,
35.0–39.9, or X40.0 kgm–2).
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Psoriasis occurs in a bimodal age distribution. Type 1
psoriasis is generally early onset, whereas type 2 psoriasis is
late onset (Henseler and Christophers, 1985; Langley et al.,
2005). In this study, elevated risk for incident T2D was
initially observed for NHS II, whereas the multivariate-
adjusted RRs for NHS and HPFS were close to null. The
three cohorts have different age distributions. For NHS II,
even until the June of 2005, all were younger than 60 years.
For NHS, the baseline mean age was more than 60 years. For
HPFS, the baseline mean age was more than 50 years. Given
that psoriasis and T2D share some common risk factors,
individuals with type 1 psoriasis may have a higher risk of
developing T2D. On the basis of this rationale and the
different age distribution in the three cohorts, we hypothe-
sized that age may be an effect modifier of the association
between psoriasis and T2D.
By only including those younger than 60 years during the
follow-up for NHS and HPFS, results indicated increased risk
of incident T2D associated with psoriasis, although not
significant because of the small number of exposed cases.
When performing pooled analysis, we observed that psoriasis
was associated with a markedly increased risk of incident
T2D for women and men younger than 60 years during the
follow-up. It must be acknowledged herein that our meta-
analysis is exploratory. Because the study design across these
three cohorts is very similar, we applied a meta-analytic
approach to pool the results, allowing for the appropriate
controlling for different covariates in the three cohorts. Test of
heterogeneity for these younger participants among three
cohorts did not show significance.
Among younger participants, although we had limited
power to analyze the impact of psoriasis diagnosis age on risk
of T2D among NHS and HPFS after excluding baseline
psoriasis, we did such analyses among NHS II participants.
Our results indicated that for individuals developing psoriasis
at an early age, the risk of developing T2D was much higher,
whereas among those with psoriasis at late onset, the risk was
lower. Although we cannot define the specific proportion
with type 1 psoriasis, the majority of younger individuals with
psoriasis may be type 1.
Past studies have underscored the importance of adiposity
as a major determinant of diabetes (Weinstein et al., 2004). In
our models, although we have shown an independent
association between psoriasis and T2D from BMI, the RR
adjusting for BMI and age is very similar to the final
multivariate-adjusted RR. Therefore, BMI is a major factor
leading to the decline of RRs after multivariate adjustment.
Considering the metabolic consequences of adiposity in the
development of psoriasis (Setty et al., 2007a) and diabetes,
BMI remains an important, possibly intermediate, pathway
affecting the association between psoriasis and T2D.
We had confirmed the diagnosis of psoriasis for NHS and
NHS II. Sensitivity analysis using the confirmed psoriatics
indicated that psoriasis was associated with a significantly
elevated risk of developing T2D. Compared with the analysis
using the self-reported cases, the magnitude of effect
estimates was similar, which demonstrated the reproduci-
bility of our results.
It is well accepted that there is ‘‘common soil’’ underlying
the developing of diabetes and cardiovascular diseases (Stern,
1995). Moreover, a close link exists between diabetes and
cancer (Giovannucci et al., 2010). A sensitivity analysis by
excluding those with baseline cancer or cardiovascular
diseases did not cause material change in our results. In
addition, to reduce reverse causality bias, all analyses were
repeated by excluding T2D cases that occurred within the
first follow-up period and the results did not change
markedly.
This study has several unique strengths. The participants
came from three large cohorts of health professionals,
including men and women and multiple age groups, and a
large number of T2D incidents were identified prospectively.
We were able to control for potential confounders, thereby
minimizing the effect of residual confounding. Ascertainment
Table 3. Relative risks of incident type 2 diabetes
according to psoriasis among younger (o60 years
during the follow-up) US women and men1
Study
Diabetes
cases
Person-
years
Age-adjusted
RR (95% CI)
Multivariate
RR (95% CI)2
NHS
No psoriasis 733 165,508 1.00 1.00
Psoriasis 23 2,982 1.73
(1.14–2.62)
1.35
(0.89–2.05)
HPFS
No psoriasis 622 245,644 1.00 1.00
Psoriasis 23 6,610 1.30
(0.86–1.97)
1.20
(0.79–1.82)
NHS/NHS II
No psoriasis 4,568 1,636,217 1.00 1.00
Psoriasis 156 29,141 1.76
(1.50–2.06)
1.26
(1.08–1.48)
NHS/NHS II/HPFS
No psoriasis 5,190 1,881,861 1.00 1.00
Psoriasis 179 35,751 1.69
(1.46–1.96)
1.26
(1.08–1.46)
Abbreviations: CI, confidence interval; HPFS, Health Professionals’
Follow-Up Study; NHS, Nurses’ Health Study; RR, relative risk.
1NHS II data not shown because study participants were all o60 years
during the follow-up, the same as in Table 2.
2Simultaneously adjusted for age, body mass index (o21.0, 21.0–22.9,
23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9, or
X40.0 kgm–2), smoking (never, past, and current with 1–14, 15–24,
or X25 cigarettes per day), alcohol intake (no, o4.9, 5.0–14.9, or
X15.0 g day–1), physical activity (o3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9,
or X27.0 metabolic equivalent hours per wk), race (Caucasian, Asian,
Hispanic, or African American), family history of diabetes (yes or no),
hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin
use (yes or no), multivitamin use (yes or no), and postmenopausal
hormone use (for women only, premenopause, never, current, or past
users).
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of the outcome, T2D, was validated. Ascertainment of the
exposure, psoriasis, was assessed as self-reports from health
professionals. We also had access to a large number of
confirmed cases with psoriasis, and were able to replicate
findings obtained from self-reported cases. Moreover, to
ensure the precision of the results, different sensitivity
analyses were performed. Considering the possible compet-
ing morbidities, we applied sensitivity analyses by excluding
cardiovascular disease and cancer and observed no material
change in the results.
Several limitations are worth considering. First, misclassi-
fication is possible as physician diagnosis of psoriasis was
collected retrospectively and was not confirmed for HPFS.
We cannot obtain information for individuals with psoriasis
who died before the data collection. Potential recall bias may
also be caused by retrospective data collection. However, the
health-care–related professional background of our partici-
pants was reassuring and the relatively higher accuracy of
their report would have tended to cause nondifferential
misclassification of T2D, resulting in a conservative estimate
of RR. Furthermore, we have completed three waves of
validation study for psoriasis in NHS and NHS II. A previous
study found that psoriasis self-reports had 490% accuracy
(Dominguez et al., 2009). Actually, the results from
confirmed cases further replicate the results using self-
reported cases in NHS and NHS II. Moreover, we compared
the characteristics between those responding and not
responding to the psoriasis question. The main character-
istics, such as age and BMI, were similar. For NHS, NHS II,
and HPFS, the proportion of T2D cases in responders was
55.8, 89.3, and 53.3%, whereas the proportion of responders
in the total participants was 56.9, 83.5, and 51.5%,
respectively. Therefore, it is less likely that our results were
greatly distorted by response bias. Second, we did not have
information on severity of psoriasis and cannot evaluate the
trend of risk for T2D by psoriasis severity. Third, information
on psoriasis-related therapy was unavailable. It is worth
noting that systemic steroids are not the standard of care for
psoriasis in the United States and adherence to long-term use
of topical steroid is generally low as steroids tend to worsen
cutaneous manifestations of psoriasis (Brodell and Williams,
1999; Zaghloul and Goodfield, 2004). Hence, there is little
concern regarding the gluconeogenic impact of systemic
steroid therapy in our study (Gomez and Frost, 1976). It was
reported that tumor necrosis factor blocker could have a
positive influence on body weight (Saraceno et al., 2008).
However, we comprehensively adjusted for the roles of BMI.
Fourth, as our study is observational, we cannot rule out the
Table 4. Association of psoriasis diagnosis age with incidence of type 2 diabetes (NHS II)
Psoriasis diagnosis age Diabetes cases Person-years Age-adjusted RR (95% CI) Multivariate RR (95% CI)1
No psoriasis 3,835 1,470,709 1.00 1.00
Diagnosis age o40 y 18 2,503 3.09 (1.94–4.92) 1.81 (1.14–2.89)
Diagnosis age 40–49 y 24 2,318 2.41 (1.61–3.60) 1.31 (0.88–1.96)
Diagnosis age X50 y 2 589 0.60 (0.15–2.40) 0.48 (0.12–1.94)
Abbreviations: CI, confidence interval; NHS, Nurses’ Health Study; RR, relative risk.
1Simultaneously adjusted for age, body mass index (o21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9, orX40.0 kgm–2),
smoking (never, past, and current with 1–14, 15–24, or X25 cigarettes per day), alcohol intake (no, o4.9, 5.0–14.9, or X15.0 g day–1), physical activity
(o3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, orX27.0 metabolic equivalent hours per wk), race (Caucasian, Asian, Hispanic, or African American), family history of
diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multivitamin use (yes or no), and
postmenopausal hormone use (premenopause, never, current, or past users).
Table 5. Association of psoriasis with incidence
of type 2 diabetes in confirmed cases of psoriasis
(NHS and NHS II)
Sensitivity
analysis
Diabetes
cases
Person-
years
Age-adjusted
RR (95% CI)
Multivariate
RR (95% CI)1
NHS
For all participants
No psoriasis 4,198 725,208 1.00 1.00
Psoriasis 82 10,456 1.33
(1.07–1.66)
1.14
(0.92–1.42)
For participants younger than 60 years
No psoriasis 738 166,169 1.00 1.00
Psoriasis 18 2,321 1.73
(1.08–2.76)
1.40
(0.87–2.23)
NHS II
No psoriasis 3,891 1,483,100 1.00 1.00
Psoriasis 77 13,768 1.92
(1.53–2.40)
1.46
(1.16–1.83)
Abbreviations: CI, confidence interval; NHS, Nurses’ Health Study; RR,
relative risk.
1Simultaneously adjusted for age, body mass index (o21.0, 21.0–22.9,
23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9, or
X40.0 kgm–2), smoking (never, past, and current with 1–14, 15–24,
or X25 cigarettes per day), alcohol intake (no, o4.9, 5.0–14.9, or
X15.0 g day–1), physical activity (o3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9,
or X27.0 metabolic equivalent hours per wk), race (Caucasian, Asian,
Hispanic, or African American), family history of diabetes (yes or no),
hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin
use (yes or no), multivitamin use (yes or no), and postmenopausal
hormone use (premenopause, never, current, or past users).
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possibility of residual confounding by additional unmeasured
or imperfectly measured confounders. Fifth, the majority of
study participants are of European ancestry, which limits
generalizing the results to other ethnicities.
In conclusion, our prospective study has provided further
evidence that individuals developing psoriasis at a younger
age are at a significantly elevated risk of T2D. This finding
further underscores that psoriasis is a systemic inflammatory
disorder. The suggested association demonstrating psoriasis
as a risk predictor for T2D could hold general public health
significance. Further work on the contributing mechanisms
underlying this association is warranted.
MATERIALS AND METHODS
Study population
The NHS was established in 1976 when 121,700 married, female
registered nurses aged 30–55 years in the United States returned
a baseline questionnaire about their medical history and lifestyle.
NHS II was initially established in 1989 when 116,671 female
nurses aged 25–42 years returned a baseline questionnaire. The
HPFS began in 1986 when 51,529 men in health professions
completed their baseline questionnaire (Supplementary Table S1
online). Biennially, participants receive a questionnaire, and a
response rate exceeding 90% has been achieved in each follow-up
cycle. The institutional review board of the Partners Health Care
System approved this study. Participants’ completion and return of
the self-administered questionnaire was considered to imply
informed consent.
Assessment of main exposure (psoriasis)
In 2008, the NHS participants were asked whether they had psoriasis
diagnosed by medical provider and the date of diagnosis (1997 or
before, 1998–2001, 2002–2005, 2006–2007, or 2008). Of the 69,243
responders, a total of 2,161 nurses reported having been diagnosed
with psoriasis; 1,334 were prevalent cases at baseline (1997 or
before) and 827 occurred afterwards.
In 2005, NHS II participants were asked whether they had
psoriasis diagnosed by medical provider and the date of diagnosis
(before 1991, 1991–1994, 1995–1998, 1999–2002, or 2003–2005).
Of the 97,476 responders, 2,529 women reported being diagnosed
with psoriasis; 1,378 were prevalent cases at baseline (before 1991)
and 1,151 occurred afterwards.
In 2008, HPFS participants were asked whether they had
psoriasis diagnosed by medical provider and the date of diagnosis
(before 1986, 1986–1990, 1991–1995, 1996–2000, 2001–2004, or
2005–2008). Of the 25,635 responders, 1,171 reported being
diagnosed with psoriasis; 600 were prevalent cases at baseline
(before 1986) and 571 occurred afterwards.
For NHS and NHS II, we confirmed self-reported psoriasis by
using the Psoriasis Screening Tool questionnaire (Dominguez et al.,
2009). Briefly, this is a one-page self-administered questionnaire
inquiring about being diagnosed with psoriasis by some type of
medical provider and psoriasis phenotypes. On the basis of multiple
a priori hypotheses, scoring algorithms were developed to assign a
diagnosis of psoriasis depending on the response to the questions.
The screening tool can reach 99% sensitivity and 94% specificity
when screening for psoriasis (Dominguez et al., 2009). We mailed it
to participants who self-reported a diagnosis of psoriasis and the
response rate reached 87% and the confirmation rate was 92% in
NHS II.
Follow-up and assessment of outcome
The end point is diagnosis of T2D. On the baseline and biennial
questionnaires, participants responded to a question on physician-
diagnosed T2D. For those reporting diabetes, a supplementary
questionnaire was then sent for confirmation of the report and
ascertainment of the date of diagnosis. The diagnosis was confirmed
if at least one of the criteria of the National Diabetes Data Group
were met (He et al., 2010). The diagnostic procedure has been
verified and reached validity of 98% after medical record review
by an endocrinologist blinded to the questionnaire information
(Manson et al., 1991). Moreover, a substudy on the prevalence
of undiagnosed diabetes suggested a very low false-negative rate
(Field et al., 2001).
Statistical analysis
In NHS, after exclusion of baseline diabetes (N¼ 4,182), uncon-
firmed or type 1 diabetes (N¼ 969), and missing date of psoriasis
(N¼ 165), 63,927 participants and 1,604 psoriasis cases as of 2005
were included for analyses. In NHS II, after exclusion of baseline
diabetes (N¼ 159), unconfirmed or type 1 diabetes (N¼ 1,482), and
missing date of psoriasis (N¼ 56), 95,779 participants and 2,397
psoriasis cases as of 2002 were included for analyses. In HPFS,
after exclusion of baseline diabetes (N¼ 349), unconfirmed or
type 1 diabetes (N¼ 570), and missing date of psoriasis (N¼ 27),
24,689 participants and 913 psoriasis cases as of 2004 were
included. Person-years of follow-up for each participant were
calculated from the return date of baseline questionnaire (1996
for NHS, 1991 for NHS II, and 1986 for HPFS) to the date of
diagnosis of T2D, or the end of follow-up (June 2008 for NHS, June
2007 for NHS II, and January 2006 for HPFS), whichever came first.
We used the Cox proportional hazards analysis stratified by age and
a 2-year follow-up interval to estimate the age-adjusted and
multivariate RR and 95% CI for the association between psoriasis
and incident T2D.
The time-varying covariates adjusted in the multivariate analysis
were updated during follow-up, including age, BMI, smoking status,
physical activity, alcohol intake, race, family history of diabetes,
hypertension, hypercholesterolemia, current aspirin use, multivita-
min use, menopausal status, and postmenopausal hormone use
(for women only).
Further analyses were performed for NHS and HPFS by including
only those younger than 60 years during the follow-up (for NHS II,
all met this criteria). Then, pooled analysis was conducted using
a meta-analytic approach to evaluate the pooled RR for T2D
by psoriasis among participants younger than 60 years during the
follow-up from the three cohorts. We tested the heterogeneity
between studies and estimated the overall association from random
effects (weighted proportionately to the inverse of the sum of the
study-specific variance plus the common variance between studies)
or fixed effects models (weighted proportionately to the inverse
of the study-specific variance; Smith-Warner et al., 2006).
For analysis of psoriasis diagnosis age and T2D in NHS II, we
excluded psoriasis before baseline because we had no information
on their diagnosis date. Age at diagnosis was categorized into three
groups (o40, 40–49, and X50 years).
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We also performed a sensitivity analysis by excluding partici-
pants who had a history of cardiovascular disease or cancer at
baseline or had reported any of these conditions on a previous
questionnaire. In addition, another sensitivity analysis was carried
out by excluding diabetes occurring within the first 2-year time
period of follow-up.
All statistical analyses were conducted using the Statistical
Analysis System software (SAS, version 9.1; SAS Institute, Cary,
NC). All statistical tests were two tailed, and the significance level
was set at Po0.05.
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